A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Stefan Knop, Monika Szarejko, Norbert Grząśko, Sara Bringhen, Karolin Trautmann‐Grill, Artur Jurczyszyn, Angelo Vacca, Cyrus Khandanpour, Barbara Gamberi, Ludek Pour, Katrine F. Iversen, Michael T. Stumpp, Cosima Suter, Keith M. Dawson, Christof Zitt, Philippe Legenne, Vaia Stavropoulou, Martin F. Fey, Nicolas Leupin, Hartmut Goldschmidt
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	eJHaem
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
DOI:	10.1002/jha2.968

Similar Items